missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ VHLL Polyclonal Antibody
Description
This target displays homology in the following species: Human: 100%.
Von Hippel-Lindau (VHL) tumor suppressor protein is a component of an E3 ubiquitin ligase complex that selectively ubiquitinates the alpha subunit of the hypoxia-inducible factor (HIF) transcription factor for proteasome-mediated degradation. Inactivation of VHL causes VHL disease and sporadic kidney cancer. This gene encodes a VHL homolog that lacks one of two key domains necessary for VHL function. This gene may contribute to the regulation of oxygen homeostasis and neovascularization during placenta development. This gene is intronless, and can also be interpreted as a retrotransposed pseudogene of the VHL locus located on chromosome 3. The same publication also indicates that this protein binds HIF alpha but fails to recruit the E3 ubiquitin ligase complex, and it therefore functions as a dominant-negative VHL protein and a protector of HIF alpha.
Specifications
Specifications
| Antigen | VHLL |
| Applications | Western Blot |
| Classification | Polyclonal |
| Concentration | 0.5 mg/mL |
| Conjugate | Unconjugated |
| Formulation | PBS with 2% sucrose and 0.09% sodium azide |
| Gene | VHLL |
| Gene Accession No. | Q6RSH7 |
| Gene Alias | VHL pseudogene; VHLL; VHL-like protein; VHLP; VLP; von Hippel-Lindau tumor suppressor like; von Hippel-Lindau tumor suppressor-like; von Hippel-Lindau-like protein |
| Gene Symbols | VHLL |
| Show More |
Product Title
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
Spot an opportunity for improvement?